O
PBYI icon

OrbiMed’s Puma Biotechnology PBYI Stock Holding History

OrbiMed’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-636,600
Closed -$6.85M – 142
2019
Q3 		$6.85M Buy
636,600
+12,351
+2% +$133K 0.13% 86
2019
Q2 		$7.93M Sell
624,249
-1,255,751
-67% -$28.9M 0.12% 96
2019
Q1 		$72.9M Sell
1,880,000
-718,883
-28% -$22M 1.13% 26
2018
Q4 		$52.9M Sell
2,598,883
-106,298
-4% -$3.19M 0.98% 32
2018
Q3 		$124M Sell
2,705,181
-27,700
-1% -$1.34M 1.49% 21
2018
Q2 		$162M Buy
2,732,881
+91,220
+3% +$5.29M 1.93% 12
2018
Q1 		$180M Buy
2,641,661
+457,126
+21% +$34.2M 2.23% 11
2017
Q4 		$216M Sell
2,184,535
-241,200
-10% -$27M 2.73% 8
2017
Q3 		$290M Hold
2,425,735
– – 2.78% 7
2017
Q2 		$212M Buy
2,425,735
+179,810
+8% +$10.1M 2.22% 13
2017
Q1 		$83.5M Sell
2,245,925
-29,900
-1% -$1.09M 0.95% 34
2016
Q4 		$69.9M Sell
2,275,825
-107,700
-5% -$4.66M 0.89% 38
2016
Q3 		$160M Sell
2,383,525
-580,500
-20% -$29.4M 1.82% 16
2016
Q2 		$88.3M Buy
2,964,025
+210,600
+8% +$6.58M 0.92% 38
2016
Q1 		$80.9M Buy
2,753,425
+514,600
+23% +$23.3M 0.85% 37
2015
Q4 		$176M Buy
2,238,825
+1,043,325
+87% +$81.9M 1.59% 19
2015
Q3 		$90.1M Buy
1,195,500
+254,700
+27% +$24.1M 0.91% 38
2015
Q2 		$110M Buy
940,800
+570,600
+154% +$103M 0.92% 33
2015
Q1 		$87.4M Buy
370,200
+119,300
+48% +$25.5M 0.75% 41
2014
Q4 		$47.5M Buy
250,900
+38,000
+18% +$8.43M 0.45% 53
2014
Q3 		$50.8M Sell
212,900
-5,200
-2% -$1.07M 0.53% 48
2014
Q2 		$14.4M Buy
+218,100
New +$15.5M 0.17% 72
2013
Q3 		– Sell
-295,000
Closed -$13.1M – 130
2013
Q2 		$13.1M Buy
+295,000
New +$10.4M 0.28% 64

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's PBYI Position: Q4 2019 in Review

OrbiMed sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 636,600 shares — an estimated $6.85M sold.

OrbiMed first reported a position in PBYI in Q2 2013 and held it in 23 quarters. The position peaked at $290M in Q3 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • OrbiMed reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • OrbiMed sold 636,600 Puma Biotechnology shares in Q4 2019, an estimated $6.85M.
  • OrbiMed first reported a position in Puma Biotechnology in Q2 2013 and held it in 23 quarters.
  • OrbiMed's Puma Biotechnology position peaked at $290M in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.